Cover Image
市場調查報告書

Zoledronic acid的中國市場分析

Investigation Report on China Zoledronic Acid Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 333633
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Zoledronic acid的中國市場分析 Investigation Report on China Zoledronic Acid Market, 2010-2019
出版日期: 2015年06月25日 內容資訊: 英文 30 Pages
簡介

中國國內每年產生300萬人以上的新癌症患者,其中約50%為骨轉移性癌症的患者。Zoledronic acid 是2000年在加拿大,2001年在美國認證的藥物,由於阻礙溶骨細胞的活動,使骨吸收之速度減低,降低癌症患者併發骨轉移性癌症的可能性。Zoledronic acid在中國國內的上市以來,急速擴大其年度銷售額,2005年是1200萬人民幣,2014年到4億7400萬人民幣,以年複合成長率(CAGR) 52%的速度成長。

本報告提供中國的Zoledronic acid的市場相關分析、整體市場規模趨勢(過去5年份)和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來性的市場趨勢預測(今後5年份)等調查評估。

第1章 Zoledronic acid的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Zoledronic acid市場概況

  • 中國國內的Zoledronic acid的專利申請、認證情形
  • 主要製造商
  • 市場規模

第3章 Zoledronic acid銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Zoledronic acid市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的Zoledronic acid市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 Zoledronic acid的醫院用標準價格

  • Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd (商標名:Zhuolai)
  • Sichuan Hairong Pharmaceutical Co., Ltd (商標名:Suqi)
  • Jiangsu Hengrui Medicine Co., Ltd (商標名:Ailang)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd (商標名:Tianqing Yitai)
  • Novartis (瑞士) (商標名:Zometa)

第7章 中國國內的Paclitaxel的主要製造商

  • Novartis
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • Jiangsu Hengrui Medicine Co., Ltd
  • Sichuan Hairong Pharmaceutical Co., Ltd
  • Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd

第8章 中國的Zoledronic acid市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506238

Malignancy with bone metastases is common in patients with advanced tumor like breast cancer, lung cancer, prostate cancer and multiple myeloma. Since patients with breast cancer or prostate cancer have relatively long median survival time, they still face the problem of treating bone metastases. Meanwhile, patients with lung cancer also need to pay attention to bone metastases despite their short median survival due to lung cancer's high incidence. The complications of bone metastases include bony pain, pathological fracture, spinal cord compression and hypercalcemia. The most common drug for bone metastases is diphosphonate. Three generations of diphosphonate, respectively, etidronate and clodronate representated by Bonefos, pamidronate and alendronate sodium represented by Bonin as well as sodium ibandronate and zoledronic acid are now used in the clinic.

Developed by Novartis, zoledronic acid first appeared in the market in Canada in Oct. 2000 and then in May, it entered Britain. In Aug. 2001, it was approved by FDA to be sold under the trade name of Zometa. As the new generation of diphosphonate, zoledronic acid can inhibit the activity of osteoclasts, slow down bone resorption and reduce the incidence of bone metastases in cancer patients. Compared with pamidronate, zoledronic acid is more effective in inhibiting hypercalcemia in patients with multiple myeloma or solid tumor, alleviating pain, delaying bone metastases and other complications.

Each year, the number of new cases of cancer in China reaches more than 3 million, among which about 50% is with bone metastases. Zoledronic acid develops fast after entering China, annual sales value rising from less than CNY 12 million in 2005 to CNY 474 million in 2014 and CAGR during this period reaching 52%. Novartis (Switzerland), Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd, Sichuan Hairong Pharmaceutical Co., Ltd and Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd occupy the majority of the market share, among which Novartis (Switzerland) has the largest market share of over 70% for sales value in 2014.

Readers can get at least the following information from this report:

  • market size of zoledronic acid in China
  • competitive landscape of zoledronic acid in Chinese market
  • price of zoledronic acid made by different enterprises in China
  • market outlook of zoledronic acid in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-tumor drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Zoledronic Acid

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Zoledronic Acid in China

  • 2.1. Patent and Approval Status of Zoledronic Acid in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Zoledronic Acid in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Zoledronic Acid in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Zoledronic Acid in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Zoledronic Acid in Chinese Hospitals in 2014

  • 6.1. Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd (Trade Name: Zhuolai)
  • 6.2. Sichuan Hairong Pharmaceutical Co., Ltd (Trade Name: Suqi)
  • 6.3. Jiangsu Hengrui Medicine Co., Ltd (Trade Name: Ailang)
  • 6.4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Tianqing Yitai)
  • 6.5. Novartis (Switzerland) (Trade Name: Zometa)

7. Major Manufacturers of Zoledronic Acid in Chinese Market, 2010-2014

  • 7.1. Novartis
  • 7.2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • 7.3. Jiangsu Hengrui Medicine Co., Ltd
  • 7.4. Sichuan Hairong Pharmaceutical Co., Ltd
  • 7.5. Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd

8. Market Outlook of Zoledronic Acid in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Zoledronic Acid in China
  • Chart Sales Status of Zoledronic Acid in China
  • Chart Sales Value of Zoledronic Acid in China, 2010-2014 (unit in CNY million)
  • Chart Sales Value of Zoledronic Acid in Some Regions in China, 2010-2014 (unit in CNY million)
  • Chart Sales Volume of Zoledronic Acid in China, 2010-2014 (unit: million)
  • Chart Sales Volume of Zoledronic Acid in Some Regions in China, 2010-2014 (unit: thousand)
  • Chart Market Share of TOP3 Manufacturers of Zoledronic Acid for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Zoledronic Acid Made by Novartis (Switzerland) in China, 2010-2014
  • Chart Sales Value and Market Share of Zoledronic Acid Made by Chia Tai Tianqing in China, 2010-2014
  • Chart Sales Value and Market Share of Zoledronic Acid Made by Jiangsu Hengrui in China, 2010-2014
  • Chart Sales Value and Market Share of Zoledronic Acid Made by Other Enterprises in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Zoledronic Acid for Sales Volume in China, 2010-2014
  • Chart Sales Volume and Market Share of Zoledronic Acid Made by Novartis (Switzerland) in China, 2010-2014
  • Chart Sales Volume and Market Share of Zoledronic Acid Made by Chia Tai Tianqing in China, 2010-2014
  • Chart Sales Volume and Market Share of Zoledronic Acid Made by Jiangsu Hengrui in China, 2010-2014
  • Chart Sales Value and Market Share of Zoledronic Acid Injection in China, 2010-2014
  • Chart Sales Volume and Market Share of Zoledronic Acid Injection in China, 2010-2014
  • Chart Price of Zoledronic Acid Made by Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Zoledronic Acid Made by Sichuan Hairong Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Zoledronic Acid Made by Jiangsu Hengrui Medicine Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Zoledronic Acid Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Zoledronic Acid Made by Novartis (Switzerland) in Some Chinese Cities in 2014
Back to Top